BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
1/06/2015 - NAD Recommends Novartis Discontinue Onset-of-Action Claim for Theraflu, following Pfizer Challenge
The National Advertising Division has recommended that Novartis Consumer Health Inc., discontinue the advertising claim that “Theraflu Multi-Symptom Severe Cold” “starts to get to work in your body in 5 minutes.” The claim was challenged by Pfizer Consumer Healthcare, a competing manufacturer of cold and cough relief products. -
1/05/2015 - NAD Refers Advertising Claims from Cortec Corp. to FTC for Further Review
The National Advertising Division has referred to the Federal Trade Commission (FTC) advertising claims made by Cortec Corporation, the maker of vapor corrosion inhibiting (VCI) products, after the advertiser declined to participate in a self-regulatory review of its advertising claims. -
12/23/2014 - NAD Refers Advertising for Obesity Research Council’s ‘Lipozene’ to FTC for Review after Advertiser Declines to Participate in NAD Proceeding
The National Advertising Division has referred advertising for Lipozene, a product marketed by the Obesity Research Council, to the Federal Trade Commission (FTC) after the company declined to participate in NAD’s review of its advertising claims. -
12/17/2014 - NAD Examines Fareportal’s Search Engine Marketing in Challenge Brought by Expedia
The National Advertising Division has recommended that online travel agent Fareportal Inc. – operator of the CheapOair.com and OneTravel.com sites –discontinue certain claims in its search engine marketing as the claims could potentially mislead consumers when they appear in response to consumer searches. -
12/04/2014 - Sumo Logic Discontinues Express, Implied Claims Challenged by Splunk
Sumo Logic, Inc., the maker of software for log management and analytic systems, has said it will discontinue all advertising claims challenged before the National Advertising Division (NAD) by competitor Splunk, Inc. -
12/03/2014 - NAD Recommends ADD-Care Discontinue Claims for Supplement Promoted for ‘Help’ with ADD, ADHD Symptoms
The National Advertising Division has recommended that ADD-care, the maker of the dietary supplement ADD-care, discontinue all claims for the product reviewed by NAD in a recent proceeding. -
11/26/2014 - NARB Panel Recommends Reckitt Benckiser Discontinue Challenged ‘8-Minute’ Relief Claims for Mucinex, Maximum Strength Mucinex
A panel of the National Advertising Review Board (NARB) has recommended that Reckitt Benckiser, LLC (RB) discontinue challenged advertising claims for the company’s Mucinex and Maximum Strength Mucinex bi-layer tablet products. -
11/24/2014 - NAD Recommends AT&T Modify Certain ‘U-Verse’ Ads to Better Disclose Limitations of Service, Discontinue TV Spots; Finds Advertiser Provided ‘Reasonable Basis’ for Speed Claim
The National Advertising Division has recommended that AT&T Services, Inc., modify disclosures that accompany certain advertised Internet speed claims made for the company’s U-verse service. -
11/20/2014 - CARU Recommends BSA Modify Website to Better Protect Children’s Privacy; BSA Agrees to Do So
The Children’s Advertising Review Unit has recommended that Boys Scouts of America modify its website, Boyslife.org, to assure that information collection practices are in compliance with CARU guidelines and the Children’s Online Privacy Protection Act (COPPA). -
11/19/2014 - NAD Recommends ‘LifeCaps’ Discontinue all Claims Challenged by CRN
The National Advertising Division has recommended that LifeCaps Neutraceuticals, LLC, discontinue all challenged advertising claims for the company’s “LifeCaps,” a dietary supplement promoted as a “survival pill.”